跳至主要内容
临床试验/NCT02063308
NCT02063308已完成不适用

Oxaloacetate Pharmacokinetics and Safety

Russell Swerdlow, MD2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2014年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6
试验地点
2
主要终点
Correlation between oral OAA intake and plasma levels

研究概览

简要总结

By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet criteria for Mild or Moderate AD
  • Have a study partner
  • Speak English as primary language.

排除标准

  • Absence of a study partner
  • Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)

结局指标

主要结局

Correlation between oral OAA intake and plasma levels

时间窗: Change from dose to 30, 45, 60, 75, 90, 105, 120, 135, 150, and 240 minutes after dosing

Baseline blood sample will be obtained before 100 mg OAA is administered. Blood samples to be drawn every 15 minutes starting 30 minutes after OAA administration.

次要结局

  • safety of OAA in study participants(Change from Baseline to Month 1)

研究者

发起方
Russell Swerdlow, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Russell Swerdlow, MD

Gene and Marge Sweeney Professor of Neurology

University of Kansas Medical Center

研究点 (2)

Loading locations...

相似试验